DE69026620D1 - Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten - Google Patents

Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten

Info

Publication number
DE69026620D1
DE69026620D1 DE69026620T DE69026620T DE69026620D1 DE 69026620 D1 DE69026620 D1 DE 69026620D1 DE 69026620 T DE69026620 T DE 69026620T DE 69026620 T DE69026620 T DE 69026620T DE 69026620 D1 DE69026620 D1 DE 69026620D1
Authority
DE
Germany
Prior art keywords
histamine
subject
agent
analogs
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69026620T
Other languages
English (en)
Other versions
DE69026620T2 (de
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Syntello Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Inc filed Critical Syntello Inc
Publication of DE69026620D1 publication Critical patent/DE69026620D1/de
Application granted granted Critical
Publication of DE69026620T2 publication Critical patent/DE69026620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69026620T 1989-09-19 1990-09-19 Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten Expired - Lifetime DE69026620T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19
PCT/SE1990/000599 WO1991004037A1 (en) 1989-09-19 1990-09-19 Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists

Publications (2)

Publication Number Publication Date
DE69026620D1 true DE69026620D1 (de) 1996-05-23
DE69026620T2 DE69026620T2 (de) 1996-10-02

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69026620T Expired - Lifetime DE69026620T2 (de) 1989-09-19 1990-09-19 Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten

Country Status (12)

Country Link
US (1) US5348739A (de)
EP (1) EP0493468B1 (de)
JP (1) JP2845622B2 (de)
KR (1) KR100195392B1 (de)
AT (1) ATE136786T1 (de)
AU (1) AU640954B2 (de)
CA (1) CA2066728C (de)
DE (1) DE69026620T2 (de)
DK (1) DK0493468T3 (de)
ES (1) ES2087163T3 (de)
NO (1) NO921050D0 (de)
WO (1) WO1991004037A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
WO1999019462A1 (en) 1997-10-10 1999-04-22 The Regents Of The University Of California Enhanced immunogenic cell populations prepared using h2 receptor antagonists
CA2341742A1 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
IL146745A0 (en) * 1999-07-16 2002-07-25 Maxim Pharm Inc Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
JP2006512279A (ja) * 2002-03-29 2006-04-13 マキシム ファーマシューティカルス，インコーポレイテッド 眼内損傷を治療および予防するためのｒｏｍ生成および放出阻害剤の使用
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
AU2008221358A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US20120039844A1 (en) * 2009-04-16 2012-02-16 Kristoffer Hellstrand Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
CA3068587A1 (en) * 2017-06-29 2019-01-03 Immune Pharmaceuticals, Inc. Methods of delaying and preventing acute myeloid leukemia relapse
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
JP2845622B2 (ja) 1999-01-13
AU6419190A (en) 1991-04-18
NO921050L (no) 1992-03-18
CA2066728C (en) 2001-12-25
EP0493468B1 (de) 1996-04-17
CA2066728A1 (en) 1991-03-20
WO1991004037A1 (en) 1991-04-04
ATE136786T1 (de) 1996-05-15
AU640954B2 (en) 1993-09-09
EP0493468A1 (de) 1992-07-08
NO921050D0 (no) 1992-03-18
KR920703078A (ko) 1992-12-17
JPH05504548A (ja) 1993-07-15
KR100195392B1 (ko) 1999-06-15
DE69026620T2 (de) 1996-10-02
DK0493468T3 (da) 1996-08-26
US5348739A (en) 1994-09-20
ES2087163T3 (es) 1996-07-16

Similar Documents

Publication Publication Date Title
DE69026620D1 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
Creagan et al. Phase II study of recombinant leukocyte A interferon (rIFN‐αA) in disseminated malignant melanoma
Goldstein et al. The role of interferon in cancer therapy: a current perspective
Stevenson et al. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer.
IT1205849B (it) Derivati di indolo,procedimenti per prepararli e composizioni farmaceutiche che li contengono per il trattamento di emicrania
ES8502405A1 (es) Un metodo para producir una emulsion acuosa de perfluorocarburo
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
ATE205400T1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide
TW200637565A (en) Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent
Pape et al. Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
van HAELST-PISANI et al. Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells
ES2039236T3 (es) Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.
Goodman et al. Interleukin-2 and leukemia
ES8406468A1 (es) Procedimiento para la obtencion de derivados de terc.-butanol sustituidos
Patt et al. The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma
ES8302457A1 (es) Un procedimiento para preparar soluciones acu0sas a base de una sal de sulfonamida acuosoluble, un potenciador de sulfo-namida y un aldehido.
Gold et al. Autolymphocyte therapy—I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes
Betzler et al. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up
Sporn et al. Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2
Keong et al. Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells
Ebbesen et al. An electron microscopic examination of murine plasma cell neoplasms with and without paraproteinemia
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial
Lopez et al. Thymopentin and interleukin‐2 in combination with 5‐fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: Preliminary results
Goltz The Graft-vs-Host Reaction: An Iatrogenic Model for a Number of Skin Disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MAXIM PHARMACEUTICALS,INC., SAN DIEGO, CALIF., US